Hoe verhoudt MBRX's PB Ratio zich tot zijn concurrenten?

MBRX is good value based on its Price-To-Book Ratio (0.4x) compared to the peer average (0.8x).

Hoe verhoudt MBRX's PB Ratio zich tot andere bedrijven in de US Biotechs industrie?

MBRX is good value based on its Price-To-Book Ratio (0.4x) compared to the US Biotechs industry average (1.8x).

Wat is MBRX's PB Ratio vergeleken met zijn Fair PB Ratio? Dit is de verwachte PB Ratio, rekening houdend met de verwachte winstgroei van het bedrijf, winstmarges en andere risicofactoren.

Insufficient data to calculate MBRX's Price-To-Book Fair Ratio for valuation analysis.

Wat is de reële prijs van MBRX als we kijken naar de toekomstige kasstromen? Voor deze schatting gebruiken we een Discounted Cash Flow-model.

Insufficient data to calculate MBRX's fair value for valuation analysis.

Wat is de 12-maandsprognose van de analisten en hebben we enig statistisch vertrouwen in het consensuskoersdoel?

Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine [[statistical confidence]] in agreement.

Moleculin Biotech (Nasdaq:MBRX) - Aandelenkoers, Nieuws & Analyse

MBRX Overzicht aandelen

Moleculin Biotech, Inc., een farmaceutisch bedrijf in een klinische fase, richt zich op de ontwikkeling van kandidaat-geneesmiddelen voor de behandeling van kankers en virussen.

Over het bedrijf

MBRX fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

Risicoanalyse

Makes less than USD$1m in revenue ($0)

Does not have a meaningful market cap ($7M)

Currently unprofitable and not forecast to become profitable over the next 3 years

Shareholders have been diluted in the past year

+ 1 meer risico

Moleculin Biotech, Inc. Concurrenten

Eagle Pharmaceuticals

OTCPK:EGRX

US$7.1m

Organovo Holdings

NasdaqCM:ONVO

US$7.1m

GT Biopharma

NasdaqCM:GTBP

US$6.6m

Cyclerion Therapeutics

NasdaqCM:CYCN

US$7.4m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Moleculin Biotech
Historische aandelenkoersen
Huidige aandelenkoers	US$2.45
52 Week Hoogtepunt	US$15.75
52 Week Laag	US$2.12
Bèta	1.86
11 maand verandering	3.81%
3 maanden verandering	11.36%
1 Jaar Verandering	-72.20%
33 jaar verandering	-93.54%
5 jaar verandering	-97.43%
Verandering sinds IPO	-99.66%

Recent nieuws en updates

Recent updates

We're A Little Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Rate

Dec 20

Can Moleculin Biotech (NASDAQ:MBRX) Afford To Invest In Growth?

Jul 14

Is Moleculin Biotech (NASDAQ:MBRX) In A Good Position To Deliver On Growth Plans?

Feb 18

Here's Why We're Watching Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation

Nov 01

Moleculin Biotech rises 7% as WP1096 compound selected for NIAID-funded animal studies

Sep 27

Moleculin brain cancer therapy WP1122 gets FDA orphan drug status

Sep 06

Here's Why We're Not Too Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation

Jul 11

Moleculin potential COVID drug WP1122 shows safety in preliminary data from phase 1a trial

Jul 08

Here's Why We're A Bit Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation

Jan 15

Moleculin Bio's Annamycin an Orphan Drug in U.S. for soft tissue sarcomas

Dec 29

Rendement voor aandeelhouders

	MBRX	US Biotechs	US Markt
7D	-6.5%	-0.7%	-1.6%
1Y	-72.2%	19.8%	30.8%

Rendement versus industrie: MBRX underperformed the US Biotechs industry which returned 19.8% over the past year.

Rendement versus markt: MBRX underperformed the US Market which returned 30.8% over the past year.

Prijsvolatiliteit

Is MBRX's price volatile compared to industry and market?
MBRX volatility
MBRX Average Weekly Movement	11.0%
Biotechs Industry Average Movement	9.6%
Market Average Movement	6.0%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	2.9%

Stabiele aandelenkoers: MBRX's share price has been volatile over the past 3 months compared to the US market.

Volatiliteit in de loop van de tijd: MBRX's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2015	18	Wally Klemp	moleculin.com

Moleculin Biotech, Inc, een farmaceutisch bedrijf in een klinische fase, richt zich op de ontwikkeling van kandidaat-geneesmiddelen voor de behandeling van kankers en virussen. Het belangrijkste kandidaat-geneesmiddel is Annamycine, dat zich in Fase 1B/2 van klinische studies bevindt voor de behandeling van recidief of refractaire acute myeloïde leukemie (AML) en naar de longen uitgezaaide weke delen sarcomen. Het bedrijf ontwikkelt ook WP1066, een immuun/transcriptiemodulator ontworpen om gefosforyleerde signaaltransducer en activator van transcriptie en andere oncogene transcriptiefactoren te remmen gericht op hersentumoren, alvleesklierkanker en andere kankers.

Moleculin Biotech, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Moleculin Biotech zich tot de beurswaarde?
MBRX fundamentele statistieken
Marktkapitalisatie	US$6.97m
Inkomsten(TTM)	-US$25.17m
Inkomsten(TTM)	n/a

0.0x

P/S-verhouding

-0.3x

Koers/Winstverhouding

Is MBRX overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
MBRX resultatenrekening (TTM)
Inkomsten	US$0
Kosten van inkomsten	US$0
Brutowinst	US$0
Overige uitgaven	US$25.17m
Inkomsten	-US$25.17m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-8.85
Brutomarge	0.00%
Nettowinstmarge	0.00%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde MBRX op de lange termijn?

Bekijk historische prestaties en vergelijking

MBRX Overzicht aandelen

Beloningen

Risicoanalyse

Moleculin Biotech, Inc. Concurrenten

OTCPK:EGRX

US$7.1m

NasdaqCM:ONVO

US$7.1m

NasdaqCM:GTBP

US$6.6m

NasdaqCM:CYCN

US$7.4m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

New major risk - Share price stability

Moleculin Biotech, Inc., Annual General Meeting, Oct 24, 2024

New major risk - Shareholder dilution

Moleculin Biotech, Inc. has completed a Follow-on Equity Offering in the amount of $5.497817 million.

Moleculin Biotech, Inc. Announces Plans for MIRACLE Phase 3 Pivotal Trial

Moleculin Biotech, Inc. has filed a Follow-on Equity Offering.

Recent updates

New major risk - Share price stability

Moleculin Biotech, Inc., Annual General Meeting, Oct 24, 2024

New major risk - Shareholder dilution

Moleculin Biotech, Inc. has completed a Follow-on Equity Offering in the amount of $5.497817 million.

Moleculin Biotech, Inc. Announces Plans for MIRACLE Phase 3 Pivotal Trial

Moleculin Biotech, Inc. has filed a Follow-on Equity Offering.

Moleculin Biotech, Inc. Completes End of Phase 2 Meeting with FDA for Annamycin in AML

Moleculin Biotech, Inc. Announces Additional Positive Preliminary Interim Data from AML Clinical Trial

New major risk - Market cap size

Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (Nu 21C06)

Moleculin Biotech, Inc. to Report Q1, 2024 Results on May 10, 2024

Moleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject Data

Moleculin Biotech, Inc. Announces Formation of Annamycin Scientific Advisory Board and Inaugural Appointment of Martin Tallman

New major risk - Market cap size

Moleculin Biotech, Inc Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial

New major risk - Financial position

New major risk - Share price stability

Moleculin Biotech, Inc. to Report Fiscal Year 2023 Results on Mar 22, 2024

Moleculin Biotech, Inc. Announces Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market

Moleculin Biotech, Inc. Announces 2023 Year-End Annamycin Clinical Trials Preliminary Data and 2024 Expectations for Multiple Data Readouts and Transition to Pivotal Phase 2B/3

Moleculin Biotech, Inc. announced that it expects to receive $9.01739 million in funding

We're A Little Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Rate

New major risk - Financial position

Moleculin Biotech, Inc. Announces Positive Interim Data in Annamycin Clinical Trials: MB-106 AML Trial Complete Response (CR) Rate of 38% and MB-107 STS Lung Mets Trial Median Phase 1B Extended Overall Survival of 11 Months

Moleculin Biotech, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Moleculin Biotech Receives an Extension of the 180 Calendar Days from Nasdaq to Regain Compliance with the Bid Price Requirement

New major risk - Share price stability

Moleculin Biotech, Inc. Announces Completion of Enrollment in U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases

Moleculin Biotech, Inc. Announces New Positive Independent Report of No Cardiotoxicity in Annamycin

New major risk - Financial position

Moleculin Biotech, Inc. Provides Update on Ongoing Clinical Trials

Moleculin Biotech, Inc. to Report Q2, 2023 Results on Aug 11, 2023

Can Moleculin Biotech (NASDAQ:MBRX) Afford To Invest In Growth?

Moleculin Biotech, Inc., Annual General Meeting, Jun 15, 2023

Moleculin Biotech Receives Non-Compliance Notice From Nasdaq

Moleculin Biotech, Inc. to Report Q1, 2023 Results on May 11, 2023

Is Moleculin Biotech (NASDAQ:MBRX) In A Good Position To Deliver On Growth Plans?

Moleculin Biotech, Inc. Announces Final Topline Data from Successful European Phase 1 Trial Evaluating Annamycin as Single Agent Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Moleculin Biotech, Inc. Receives Approval in Italy to Conduct Phase 1/2 Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia

Moleculin Biotech, Inc. Receives FDA Fast Track Designation of WP1122 for the Treatment of Glioblastoma Multiforme

Founder recently bought US$58k worth of stock

Founder recently bought US$108k worth of stock

Price target decreased to US$8.67

Moleculin Biotech, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Here's Why We're Watching Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation

Moleculin Biotech, Inc Provides Update on Second Multiple Ascending Dose (MAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK

Moleculin Biotech, Inc. Announces WP1096 Molecule Will Be Evaluated in Animal Studies Through the Preclinical Services Offered by the National Institute of Allergy and Infectious Diseases

Moleculin Biotech rises 7% as WP1096 compound selected for NIAID-funded animal studies

Moleculin brain cancer therapy WP1122 gets FDA orphan drug status

Moleculin Biotech, Inc. Announces Completion of Third Single Ascending Dose Cohort in Phase 1A Clinical Trial of Wp1122 in the UK

Price target decreased to US$11.67

Price target increased to US$21.50

Moleculin Concludes Phase 1B and Opens Recruitment in Phase 2 Clinical Trial of Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases

Here's Why We're Not Too Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation

Moleculin Biotech, Inc. Announces Completion of Second Single Ascending Dose (SAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK

Moleculin potential COVID drug WP1122 shows safety in preliminary data from phase 1a trial

Moleculin Biotech, Inc. Announces Completion of First Single Ascending Dose (Sad) Cohort in Phase 1A Clinical Trial of Wp1122 in the UK

Moleculin Biotech, Inc. Announces the Commencement of Dosing in Its First-In-Human Phase 1A Study to Evaluate the Safety and Pharmacokinetics (PK) of Wp1122 in Healthy Volunteers for the Treatment of COVID-19 (MB-301)

Moleculin Biotech, Inc. Announces the Commencement of Dosing in Its First-In-Human Phase 1A Study to Evaluate the Safety and Pharmacokinetics (PK) of Wp1122 in Healthy Volunteers for the Treatment of COVID-19 (MB-301)